Copenhagen, Denmark: UNION therapeutics A/S announced today that a milestone was achieved in its UNI836 collaboration with Ceva Santé Animale S.A. The milestone was triggered by confirmation from Ceva of successful completion of a clinical efficacy study of UNI836 in canine pyoderma.
“We are pleased with the results generated by Ceva. Not only do they confirm the potential of UNI836 in canine pyoderma, providing an innovative approach to an unmet medical need in veterinary care, but the data also provide strong support for the chemistry platform in human health”, states Dr. Morten Sommer, Chief Scientific Officer of UNION, and continues: “We look forward to advancing the collaboration with Ceva, and to further elucidate the potential of the platform across a broader spectrum of indications.”
Achievement of the milestone has triggered an undisclosed milestone payment to UNION.
UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. The leadership team of UNION has invented and successfully developed multiple approved human medicines. UNION is headquartered in Copenhagen (Denmark) and managed by a global team across Europe and USA.
Ceva Santé Animale is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Ceva’s mission summarised in the slogan, “Together, beyond animal health” recognises that the future health of animals, humans and our planet are inseparably bound together. Ceva is directly present in 45 countries around the world and have active business in over 110.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.